蓝帆医疗：冠脉刻痕球囊NMPA获批上市，三大特点支撑临床价值

Group 1 - The core viewpoint of the article highlights that Bluestar Medical's subsidiary, Jiwei Medical, has successfully obtained NMPA registration for its coronary artery scoring balloon catheter, Star Scar, which enhances treatment options for complex coronary artery lesions [1][2] - The Star Scar balloon catheter is designed to provide effective pre-dilation for narrowed blood vessels, particularly in cases of severe fibrosis or calcification, where conventional balloons may fail [1][2] - The product features a unique spiral-wound triangular scoring wire that allows for 360° efficient pressure-focused dilation, making it the only balloon on the market with four scoring wires, thus offering a larger scoring area [2] Group 2 - The increasing acceptance of the "intervention without implantation" concept has led to a rising usage of drug-coated balloons (DCB), emphasizing the need for adequate pre-treatment to ensure the long-term efficacy of DCBs [2] - Bluestar Medical is positioned as a leading platform enterprise in the cardiovascular field, leveraging its international and technological advantages to enhance R&D efficiency and innovation capabilities [2] - The company aims to continue its commitment to innovation, focusing on providing better medical device products for both Chinese and overseas patients, aligning with its mission to safeguard human life [3]